Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs BI 1034020 (Primary) ; BI 1034020 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 30 May 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.record.
    • 19 Mar 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
    • 30 Oct 2013 Boehringer Ingelheim has dosed the first healthy volunteers in this trial, according to an Ablynx media release. Results are expected during the second half of 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top